These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 34950454)

  • 41. Annual consultation incidence of osteoarthritis estimated from population-based health care data in England.
    Yu D; Peat G; Bedson J; Jordan KP
    Rheumatology (Oxford); 2015 Nov; 54(11):2051-60. PubMed ID: 26163287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials.
    Machado GC; Maher CG; Ferreira PH; Pinheiro MB; Lin CW; Day RO; McLachlan AJ; Ferreira ML
    BMJ; 2015 Mar; 350():h1225. PubMed ID: 25828856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT).
    Murray DW; MacLennan GS; Breeman S; Dakin HA; Johnston L; Campbell MK; Gray AM; Fiddian N; Fitzpatrick R; Morris RW; Grant AM;
    Health Technol Assess; 2014 Mar; 18(19):1-235, vii-viii. PubMed ID: 24679222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
    Hiligsmann M; Cooper C; Arden N; Boers M; Branco JC; Luisa Brandi M; Bruyère O; Guillemin F; Hochberg MC; Hunter DJ; Kanis JA; Kvien TK; Laslop A; Pelletier JP; Pinto D; Reiter-Niesert S; Rizzoli R; Rovati LC; Severens JL; Silverman S; Tsouderos Y; Tugwell P; Reginster JY
    Semin Arthritis Rheum; 2013 Dec; 43(3):303-13. PubMed ID: 23992801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial.
    Kingsbury SR; Tharmanathan P; Adamson J; Arden NK; Birrell F; Cockayne S; Dickson J; Doherty M; Dziedzic KS; Grainger A; Hewitt CE; O'Neill TW; Scott DL; Vincent TL; Wakefield RJ; Watt FE; Torgerson DJ; Conaghan PG
    Trials; 2013 Mar; 14():64. PubMed ID: 23452375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.
    Janssen MF; Pickard AS; Golicki D; Gudex C; Niewada M; Scalone L; Swinburn P; Busschbach J
    Qual Life Res; 2013 Sep; 22(7):1717-27. PubMed ID: 23184421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Global Economic Cost of Osteoarthritis: How the UK Compares.
    Chen A; Gupte C; Akhtar K; Smith P; Cobb J
    Arthritis; 2012; 2012():698709. PubMed ID: 23082249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.
    van Hout B; Janssen MF; Feng YS; Kohlmann T; Busschbach J; Golicki D; Lloyd A; Scalone L; Kind P; Pickard AS
    Value Health; 2012; 15(5):708-15. PubMed ID: 22867780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.
    Hochberg MC; Altman RD; April KT; Benkhalti M; Guyatt G; McGowan J; Towheed T; Welch V; Wells G; Tugwell P;
    Arthritis Care Res (Hoboken); 2012 Apr; 64(4):465-74. PubMed ID: 22563589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
    Herdman M; Gudex C; Lloyd A; Janssen M; Kind P; Parkin D; Bonsel G; Badia X
    Qual Life Res; 2011 Dec; 20(10):1727-36. PubMed ID: 21479777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The economic burden of osteoarthritis.
    Bitton R
    Am J Manag Care; 2009 Sep; 15(8 Suppl):S230-5. PubMed ID: 19817509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility.
    Manca A; Hawkins N; Sculpher MJ
    Health Econ; 2005 May; 14(5):487-96. PubMed ID: 15497198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
    Fenwick E; O'Brien BJ; Briggs A
    Health Econ; 2004 May; 13(5):405-15. PubMed ID: 15127421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methods for the analysis of quality-of-life and survival data in health technology assessment.
    Billingham LJ; Abrams KR; Jones DR
    Health Technol Assess; 1999; 3(10):1-152. PubMed ID: 10627631
    [No Abstract]   [Full Text] [Related]  

  • 55. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.
    Stinnett AA; Mullahy J
    Med Decis Making; 1998; 18(2 Suppl):S68-80. PubMed ID: 9566468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.
    Haar D; Sølvkjaer M; Unger B; Rasmussen KJ; Christensen L; Hansen TM
    Scand J Rheumatol; 1993; 22(3):113-8. PubMed ID: 8316771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial.
    Clark P; Casas E; Tugwell P; Medina C; Gheno C; Tenorio G; Orozco JA
    Ann Intern Med; 1993 Dec; 119(11):1067-71. PubMed ID: 8239224
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of serial measurements in medical research.
    Matthews JN; Altman DG; Campbell MJ; Royston P
    BMJ; 1990 Jan; 300(6719):230-5. PubMed ID: 2106931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of hydroxychloroquine
    Ronaldson SJ; Keding A; Tharmanathan P; Arundel C; Kingsbury SR; Conaghan PG; Torgerson DJ
    F1000Res; 2021; 10():821. PubMed ID: 34950454
    [No Abstract]   [Full Text] [Related]  

  • 60. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.